ContraFect Shares Plummet After Data Safety Monitoring Board Stops Late-Stage Staph Aureus Bacteremia Study
The Data Safety Monitoring Board (DSMB) has recommended that ContraFect’s (NASDAQ: CFRX) on going DISRUPT trial be stopped because the conditional power of the study was below the pre-specified threshold for futility.
